Le Lézard
Classified in: Health, Business
Subject: CON

Apotex Focuses on High Growth Markets with Sale of European Generics Business


Sale Part of Previously Announced Plan to Assess Global Footprint

TORONTO, July 14, 2018 /CNW/ - Apotex, Canada's largest generic pharmaceutical company, has signed an agreement to sell its commercial operations and certain supporting infrastructure for its generics business in five European countries to Aurobindo Pharma Limited.  The sale will allow Apotex to focus its resources on the Americas where strong demand for its portfolio continues.

"This is a positive move for our organization and enables us to further accelerate our efforts to drive additional growth in the Americas, while also creating manufacturing capacity to meet growing demand," said Jeff Watson, President & Chief Operating Officer, Apotex.

Apotex operates its European generic pharmaceutical business through wholly-owned subsidiaries in the Netherlands, Poland, the Czech Republic, Spain and Belgium.  Pursuant to the Agreement, these subsidiaries will be sold and certain supporting infrastructure including personnel, products, marketing authorizations and dossier license rights regarding the pharmaceutical business in those countries will effectively be transferred to Aurobindo Pharma Limited, once all closing conditions, which include customary competition clearance, are satisfied.

As part of the agreement, Apotex also entered into a transitional manufacturing and supply arrangement in order to support the ongoing growth plans of these businesses.

Apotex is a Canadian based, global pharmaceutical company, employing over 10,000 people in research, development, manufacturing and distribution facilities worldwide. Apotex is a vertically integrated business that includes generic medicines, biosimilars, active pharmaceutical ingredients and innovative pharmaceuticals. It produces more than 300 generic molecules in approximately 4,000 different dosages. For more information, please visit http://www.apotex.com

SOURCE Apotex Inc.


These press releases may also interest you

at 15:00
Focus EduSolutions, a provider of educational technology leadership to Colleges and Universities, announces a new partnership with Cambridge College to deliver five wholly online degree programs. The three undergraduate degrees and two post-graduate...

at 14:55
Dr. Howard Abrahams, who has served his community for a decade as a trusted prosthodontist, and his associate, Dr. Stan Frohlinger, is actively working with patients who do not currently qualify for dental implants due to bone loss. Without enough...

at 14:34
Ontario Nurses' Association (ONA) members seeking a new contract with the Windsor-Essex County Health Unit are holding an information picket this evening. The more than 80 Nurse Practitioners, Public Health Nurses and Registered Practical Nurses have...

at 14:20
Versant Health, a leading national managed eye health and vision plan company, is proud to announce Josh Ellis as its new Senior Director, Sales Operations. Josh has more than 14 years of successful sales operations...

at 14:18
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announced positive preliminary results in the Company's ongoing Phase 1/2 clinical trial of its human retinal progenitor cells (hRPC) cell therapy...

at 14:15
When it comes to treatment options for a damaged heart valve, nothing is getting more attention than transcatheter treatments, a minimally invasive surgical procedure in which a replacement valve is inserted without requiring patients to undergo open...



News published on 14 july 2018 at 01:00 and distributed by: